Klotho Neurosciences, Inc. (KLTO) - Dilution Analysis

10-Q filing | 121.2M shares outstanding

10-K filing | 121.2M shares outstanding

8-K filing: Klotho Neurosciences, Inc. entered into a Securities Purchase Agreement with Sigma9 Capital, Ltd. to issue and sell 3,400 shares of Series C Preferred Stock at $4,400.00 per share, convertible into common stock under certain conditions. ($14.96M proceeds)

8-K filing: Klotho Neurosciences, Inc. amended its Subscription Agreement with Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC, extending the term to September 19, 2025, and fixing the maximum number of shares applicable to the Agreement at 6,755,000.

10-Q filing | 61.4M shares outstanding

S-3 filing: Klotho Neurosciences Inc. files an S-3 to offer and sell up to $100,000,000 in the aggregate of common stock and preferred stock from time to time in one or more offerings.

8-K filing: Klotho Neurosciences, Inc. reported the sale of 6,250,000 shares of its common stock for $500,000 on June 5, 2025, in a private placement. ($0.5M proceeds)

8-K filing: The company entered into a warrant repricing agreement, reducing the exercise price of 4,515,762 outstanding Public common stock warrants to $1.35 per share and entered into a Stock Purchase Agreement for the sale of 4,000,000 shares of the Company's common stock for a total purchase price of $500,000. ($0.5M proceeds)

10-Q filing | 32.5M shares outstanding

10-K filing | 28.5M shares outstanding

S-1 filing: This is an S-1 filing by Klotho Neurosciences, Inc. to register for resale up to 43,680,219 shares of common stock, including shares issuable upon conversion of promissory notes and exercise of warrants, and shares held by existing selling stockholders.

8-K filing: Klotho Neurosciences, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell convertible promissory notes and warrants for an aggregate purchase price of $2,000,000, with the first closing resulting in the sale of a note with a principal amount of $1,086,957 and a warrant to purchase up to 2,000,000 shares of common stock for $1,000,000. ($1.0M proceeds)

8-K filing: Klotho Neurosciences, Inc. issued 2,000,000 shares of common stock to Austria Capital LLC as an inducement to purchase a convertible promissory note.

10-Q filing | 21.3M shares outstanding

S-1/A filing: This S-1/A filing registers shares of common stock issuable upon exercise of warrants and common stock held by selling shareholders.

S-1 filing: This S-1 filing details a proposed offering for up to 21,527,925 shares of common stock by selling stockholders, including shares issuable upon warrant exercises, with the company not receiving any proceeds from the resale.

10-Q filing | 15.7M shares outstanding

8-K filing: Public ANEW issued shares of common stock to Joseph Sinkule and Shalom Hirschman as reimbursement for shares due to them and assigned to pay obligations of Public ANEW at the Closing of the Business Combination, and filed an Amended Charter and Amended and Restated Bylaws.

8-K filing: Redwoods Acquisition Corporation entered into a Forward Purchase Agreement with Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC, for the potential purchase of up to 1,000,000 shares and also entered into a subscription agreement with the Seller to purchase up to 1,000,000 RWOD Shares.

10-Q filing | 5.2M shares outstanding

8-K filing: Redwoods Acquisition Corp. entered into a non-redemption agreement with certain investors where they agreed to rescind or reverse their previous election to redeem up to 360,000 shares of RWOD common stock. As of May 8, 2024, RWOD has received requests to redeem a total of 1,589,776 RWOD Shares and will have a total of 170,418 RWOD Shares outstanding following redemptions.

10-K filing | 1.8M shares outstanding

10-Q filing | 8.8M shares outstanding

8-K filing: Redwoods Acquisition Corp. issued an unsecured, non-interest bearing promissory note in the principal amount of $120,000 to Redwoods Capital LLC, RWOD's sponsor, which may be converted into shares of the Company at a price of $10.00 per share upon consummation of the Company's initial business combination.

10-Q filing | 8.8M shares outstanding

10-Q filing | 8.8M shares outstanding

10-K filing | 8.5M shares outstanding

8-K filing: Redwoods Acquisition Corp. entered into an amendment to the Investment Management Trust Agreement, issued an unsecured promissory note for $360,000 to Redwoods Capital LLC, and filed a certificate of amendment to its amended and restated certificate of incorporation to extend the deadline for an initial business combination.

10-Q filing | 14.9M shares outstanding

10-Q filing | 14.9M shares outstanding

10-Q filing | 14.9M shares outstanding

8-K filing: Redwoods Acquisition Corp. consummated its initial public offering of 10,000,000 units at $10.00 per unit, generating gross proceeds of $100,000,000, and also consummated private placements with Redwoods Capital LLC and Chardan Capital Markets, LLC, generating total proceeds of $4,775,000; the underwriters exercised the over-allotment option in full, issuing 1,500,000 units at $10.00 per unit, resulting in total gross proceeds of $15,000,000, and also consummated the private sale of additional units to the sponsor and Chardan, generating gross proceeds of $525,000. ($120.3M proceeds)

8-K filing: Redwoods Acquisition Corp. consummated its initial public offering of 10,000,000 units at $10.00 per unit, generating gross proceeds of $100,000,000, and a private placement of 477,500 units with Redwoods Capital LLC and Chardan Capital Markets, LLC, generating total proceeds of $4,775,000. ($104.78M proceeds)

8-K filing: Redwoods Acquisition Corp. completed its IPO of 10,000,000 units at $10.00 per unit, generating gross proceeds of $100,000,000, and simultaneously closed a private placement of 477,500 units with Redwoods Capital LLC and Chardan for $4,775,000. ($219.1M proceeds)

S-1/A filing: This is an S-1/A filing for an offering of common stock units with Chardan acting as the sole book-running manager.

S-1 filing: This is an S-1 filing for an offering of units, with Chardan acting as the underwriter. $10.10 per unit sold will be deposited into a trust account at Bank of America. The offering is on a firm commitment basis.